|
1
|
Pui CH and Evans WE: Treatment of acute
lymphoblastic leukemia. N Engl J Med. 354:166–178. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fielding AK, Richards SM, Chopra R, et al:
Outcome of 609 adults after relapse of acute lymphoblastic leukemia
(ALL); an MRC UKALL12/ECOG 2993 study. Blood. 109:944–950. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tavernier E, Boiron JM, Huguet F, et al:
Outcome of treatment after first relapse in adults with acute
lymphoblastic leukemia initially treated by the LALA-94 trial.
Leukemia. 21:1907–1914. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoessel R, Leclerc S, Endicott JA, et al:
Indirubin, the active constituent of a Chinese antileukemia
medicine, inhibits cyclin-dependent kinases. Nat Cell Biol.
1:60–67. 1999.PubMed/NCBI
|
|
5
|
Institute of Haematology, Chinese Academy
of Medical Sciences. Experimental and clinical studies of indirubin
in the treatment of CML. Chinese J Intern Med. 18:83–88. 1979.
|
|
6
|
Cooperative Group of Clinical Therapy of
Indirubin. Clinical studies of 314 cases of CML treated with
indirubin. Chinese J Intern Med. 1:132–135. 1980.
|
|
7
|
Marko D, Schatzle S, Friedel A, Genzlinger
A, Zankl H, Meijer L and Eisenbrand G: Inhibition of
cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human
tumour cells. Br J Cancer. 84:283–289. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jautelat R, Brumby T, Schäfer M, Briem H,
Eisenbrand G, Schwahn S, Krüger M, Lücking U, Prien O and
Siemeister G: From the insoluble dye indirubin towards highly
active, soluble CDK2-inhibitors. Chembiochem. 6:531–540. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim SA, Kim SW, Chang S, Yoon JH and Ahn
SG: 5′-nitro-indirubinoxime induces G2/M cell cycle arrest and
apoptosis in human KB oral carcinoma cells. Cancer Lett. 274:72–77.
2009.
|
|
10
|
Yoon JH, Kim SA, Kwon SM, Park JH, Park
HS, Kim YC, Yoon JH and Ahn SG: 5′-Nitro-indirubinoxime induces G1
cell cycle arrest and apoptosis in salivary gland adenocarcinoma
cells through the inhibition of Notch-1 signaling. Biochim Biophys
Acta. 1800:352–358. 2010.
|
|
11
|
Shi R, Li W, Zhang X, Zhang Y, Peng H, Xie
Y, Fan D, Liu R, Liu X and Xiong D: A novel indirubin derivative
PHII-7 potentiates adriamycin cytotoxicity via inhibiting
P-glycoprotein expression in human breast cancer MCF-7/ADR cells.
Eur J Pharmacol. 669:38–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kunz M, Driller KM, Hein M, Hohensee I,
Ramer R, Hinz B, Berger A, Eberle J and Langer P: Synthesis of
thia-analogous indirubin N-Glycosides and their influence on
melanoma cell growth and apoptosis. ChemMedChem. 5:534–539.
2010.PubMed/NCBI
|
|
13
|
Berger A, Quast SA, Plötz M, Hein M, Kunz
M, Langer P and Eberle J: Sensitization of melanoma cells for death
ligand-induced apoptosis by an indirubin derivative. Enhancement of
both extrinsic and intrinsic apoptosis pathways. Biochem Pharmacol.
81:71–81. 2011. View Article : Google Scholar
|
|
14
|
Kameswaran TR and Ramanibai R:
Indirubin-3-monooxime induced cell cycle arrest and apoptosis in
Hep-2 human laryngeal carcinoma cells. Biomed Pharmacother.
63:146–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suzuki K, Adachi R, Hirayama A, Watanabe
H, Otani S, Watanabe Y and Kasahara T: Indirubin, a Chinese
anti-leukaemia drug, promotes neutrophilic differentiation of human
myelocytic leukemia HL-60 cells. Br J Haematol. 130:681–690. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Okada H and Mak TW: Pathways of apoptotic
and non-apoptotic death in tumour cells. Nat Rev Cancer. 4:592–603.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ribas J, Bettayeb K, Ferandin Y, et al:
7-Bromoindirubin-3′-oxime induces caspase-independent cell death.
Oncogene. 25:6304–6318. 2006.
|
|
18
|
Ribas J, Yuste VJ, Garrofé-Ochoa X, Meijer
L, Esquerda JE and Boix J: 7-Bromoindirubin-3′-oxime uncovers a
serine protease-mediated paradigm of necrotic cell death. Biochem
Pharmacol. 76:39–52. 2008.
|
|
19
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshioka A, Miyata H, Doki Y, Yamasaki M,
Sohma I, Gotoh K, Takiguchi S, Fujiwara Y, Uchiyama Y and Monden M:
LC3, an autophagosome marker, is highly expressed in
gastrointestinal cancers. Int J Oncol. 33:461–468. 2008.PubMed/NCBI
|
|
21
|
Kabeya Y, Mizushima N, Ueno T, Yamamoto A,
Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T: LC3, a
mammalian homologue of yeast Apg8p, is localized in autophagosome
membranes after processing. EMBO J. 19:5720–5728. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J: Beclin 1 bridges autophagy,
apoptosis and differentiation. Autophagy. 4:947–948. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu JH, Horbinski C, Guo F, Watkins S,
Uchiyama Y and Chu CT: Regulation of autophagy by extracellular
signal-regulated protein kinases during
1-methyl-4-phenylpyridinium-induced cell death. Am J Pathol.
170:75–86. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim I, Rodriguez-Enriquez S and Lemasters
JJ: Selective degradation of mitochondria by mitophagy. Arch
Biochem Biophys. 462:245–253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mordier S, Deval C, Béchet D, Tassa A and
Ferrara M: Leucine limitation induces autophagy and activation of
lysosome-dependent proteolysis in C2C12 myotubes through a
mammalian target of rapamycin-dependent signaling pathway. J Biol
Chem. 275:29900–29906. 2000. View Article : Google Scholar
|
|
26
|
Kanazawa T, Taneike I, Akaishi R,
Yoshizawa F, Furuya N, Fujimura S and Kadowaki M: Amino acids and
insulin control autophagic proteolysis through different signaling
pathways in relation to mTOR in isolated rat hepatocytes. J Biol
Chem. 279:8452–8459. 2004. View Article : Google Scholar
|
|
27
|
Kagialis-Girard S, Mialou V, Chebel A,
Chien WW, Tigaud I, Mokdad F, Badiou C and Ffrench M: Inhibition of
normal lymphocyte proliferation by indirubin-3′-monoxime: a
multifactorial process. Leuk Lymphoma. 48:605–615. 2007.PubMed/NCBI
|
